# A Study of ARRY-438162 in Patients With Rheumatoid Arthritis

> **NCT00650767** · PHASE2 · COMPLETED · sponsor: **Array Biopharma, now a wholly owned subsidiary of Pfizer** · enrollment: 201 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** ARRY-438162, MEK inhibitor; oral
- **DRUG:** Placebo; oral

## Key facts

- **NCT ID:** NCT00650767
- **Lead sponsor:** Array Biopharma, now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2020-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00650767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00650767, "A Study of ARRY-438162 in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00650767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*